康宁公司(NYSE: GLW) today announced it will receive $204 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services through its partnership with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and Army Contracting Command. Under the agreement, Corning will substantially expand its domestic manufacturing capacity of康宁勇士州®玻璃瓶支持数十亿患者的疫苗接种和治疗。康宁将提供优先权访问指定的Barda疫苗和药物开发伙伴。
Wendell P.周，Corning的董事长和首席执行官表示，“我们很高兴Barda选择康宁作为Covid-19疫苗和治疗的包装提供商。我们的勇气玻璃提供最强大，最快的填充，最优质的药品玻璃小瓶。它有助于保护患者并解决现有的瓶颈。康宁已准备好完成对抗大流行的斗争，并帮助为未来的公共卫生紧急情况做好准备。“
在白宫在2017年，康宁加入默克和辉瑞公司宣布专注于现代化药物玻璃包装的勇气玻璃合作。通过投资在运行术曲面（OWS）下的Valor玻璃制造能力，美国政府将通过直接解决现有的限制和短缺来加强美国药物供应链。
“勇气玻璃为药品包装中的质量和性能设定了新标准。它是专门用于制药公司，独特地定位，以实现更快，更可靠的药品制造和交付 - 对SARS-COV-2大流行反应至关重要的属性，“康宁制药技术副总经理Brendan Mosher表示。
valor玻璃提供卓越的化学耐用性，最大限度地减少颗粒污染，提高产品质量。专用玻璃允许更快的填充和封盖，在常规填充线上将制造产量增加多达50％，并减少制造疫苗和疗法所需的时间。比常规硼硅酸盐玻璃更强多达10倍，valor玻璃可在制造和运输过程中降低损坏和破损，有助于确保更多的治疗方法。这种革命性玻璃具有高度专业化的制剂，该配方可用于下一代疗法，由于制造质量标准比用于传统小瓶的制造质量标准更严格。
Barda的这项批判性投资将使康宁能够在纽约大公寓的三个美国设施中加速Valor Glass'管道和小瓶制造资产的规模;北卡罗来纳州达勒姆;和朱兰，新泽西州。随着制药公司进入疫苗和治疗的最终批准，随着药物公司进入Covid-19临床试验，将有助于满足对玻璃容器的快速增长需求。
关于前瞻性陈述的谨慎
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the duration and severity of the recent COVID-19 (coronavirus) outbreak, and its ultimate impact across our businesses on demand, operations and our global supply chains; the effects of acquisitions, dispositions and other similar transactions by the Company, the effect of global business, financial, economic and political conditions; tariffs and import duties; currency fluctuations between the U.S. dollar and other currencies, primarily the Japanese yen, New Taiwan dollar, euro, Chinese yuan, and South Korean won; product demand and industry capacity; competitive products and pricing; availability and costs of critical components and materials; new product development and commercialization; order activity and demand from major customers; the amount and timing of our cash flows and earnings and other conditions, which may affect our ability to pay our quarterly dividend at the planned level or to repurchase shares at planned levels; possible disruption in commercial activities due to terrorist activity, cyber-attack, armed conflict, political or financial instability, natural disasters, or major health concerns; unanticipated disruption to equipment, facilities, IT systems or operations; effect of regulatory and legal developments; ability to pace capital spending to anticipated levels of customer demand; rate of technology change; ability to enforce patents and protect intellectual property and trade secrets; adverse litigation; product and components performance issues; retention of key personnel; customer ability, most notably in the Display Technologies segment, to maintain profitable operations and obtain financing to fund their ongoing operations and manufacturing expansions and pay their receivables when due; loss of significant customers; changes in tax laws and regulations including the Tax Cuts and Jobs Act of 2017; and the potential impact of legislation, government regulations, and other government action and investigations.
有关风险和其他因素的完整列表，请参阅我们的年度报告中描述的危险因素和前瞻性陈述，并在第10-Q上的表格10-Q.前瞻性陈述只截至他们所做的一天，康宁承诺根据新信息或未来事件毫无义务更新它们。
网络披露
根据SEC提供的指导，关于使用公司网站和社交媒体渠道披露物资信息，康宁纳入（“康宁”）希望通知投资者，媒体和其他感兴趣的缔约方它使用其网站（//www.akinfefatou.com/worldwide/en/about-us/news-events.html.）发布有关公司的重要信息，包括可能被视为投资者的资料，或补充到此或其他新闻稿中包含的信息。公司使用的网站和社交媒体渠道列表可以不时在康纳的媒体和网站上更新。康宁鼓励投资者，媒体和其他有关方面审查信息康宁可以通过其网站和社交媒体渠道公布，除了公司的证券申请，新闻稿，电话会议和网络广播之外，还可以通过上述网站和社交媒体渠道发布。
关于Corning Incorporated.
康宁（www.akinfefatou.com）是世界上领先的材料科学创新者之一，有一个169年的生命变化的发明记录。康宁在玻璃科学，陶瓷科学和光学物理学中采用其无与伦比的专业知识以及其深厚的制造和工程能力，开发用于改变行业和增强人民生活的类别定义产品。康宁通过对RD＆E的持续投资成功，是一种独特的材料和过程创新的结合，以及与作为其行业的全球领导者的客户的深度，信任关系。康宁的能力是多功能和协同作用，使公司能够发展以满足不断变化的市场需求，同时还可以帮助我们的客户在充满活力的行业中捕捉新的机遇。如今，康宁的市场包括移动消费电子，光通信，汽车技术，生命科学技术和展示技术。
操作翘曲速度
操作翘曲速度is a U.S. government-sponsored public-private partnership to facilitate, at an unprecedented pace, the development, manufacturing, and distribution of COVID-19 countermeasures, between components of HHS, including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and BARDA; the Department of Defense; private firms; and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs. Operational Warp Speed coordinates existing HHS-wide efforts, including the NIH's ACTIV partnership for vaccine and therapeutic development, NIH's RADx initiative for diagnostic development, and work by BARDA.
关于HHS，ASPL和BARDA：
HHS致力于加强和保护所有美国人的健康和福祉，为医学，公共卫生和社会服务提供有效的健康和人类服务，促进进展。ASP的使命是为了拯救生命，保护美国人免受21世纪的健康安全威胁。在ASPR中，BARDA投资于创新，先进的研发，收购和制造医疗对策 - 疫苗，药物，治疗剂，诊断工具和打击健康安全威胁所需的非药剂产品。迄今为止，55个Barda支持的产品已达到监管批准，许可或许可。了解有关联邦支持全国Covid-19回应的更多信息，请访问coronavirus.gov.。
关于JPEO-CBRND：
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) is the DoD Joint Service’s lead for development, acquisition, fielding and life-cycle support of chemical, biological, radiological, and nuclear defense equipment and medical countermeasures. As an effective acquisition program, the JPEO-CBRND puts capable and supportable systems in the hands of the service members and first responders, when and where it is needed, at an affordable price. Our vision is a resilient Joint Force, enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment, championed by innovative and state-of-the-art solutions.
